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A vaccine that provides durable immune responses is important in maintaining sustained protection against disease, both during outbreaks and outside of an outbreak for at-risk populations, such as health care and aid workers in risk areas, individuals in areas experiencing low-grade endemic disease, 2 and contacts of Ebola survivors, given evidence of prolonged shedding of the virus from body fluids with the potential for transmission. 3, 4 We report the 1-year data for the study of the Ad26.ZEBOV and MVA-BN-Filo vaccines, 1 the longest duration follow-up for any heterologous primary and booster Ebola vaccine schedule to our knowledge.
Methods | The single-center, randomized, placebo-controlled, observer-blind, phase 1 trial received approval from the National Research Ethics Service. Participants provided written The primary outcome was adverse events. Secondary outcomes were the magnitude of humoral and cellular immune responses assessed by enzyme-linked immunosorbent assay (ELISA) and enzyme-linked immunospot (ELISpot) and the percentage of vaccine responders (see Table for definitions). The number of CD4+ and CD8+ T cells and their cytokine expression patterns were assessed by intracellular cytokine staining, as exploratory outcomes. Data analysis was descriptive (SAS [SAS Institute], version 9.2) without formal statistical testing. Collection of day 360 data was a preplanned secondary analysis for vaccine recipients only; further details are available in the protocol (see the Supplement of the original publication).
Results | Of 75 active vaccine recipients, 64 attended follow-up at day 360 (median age, 39 years; women, 66%). Eleven participants withdrew (1-3 per group) and missing data were not imputed. No serious adverse events were recorded from day 240 through day 360.
All of the active vaccine recipients maintained Ebola virusspecific immunoglobulin G responses at day 360 (Figure ;  Table) . Vaccine-induced T-cell responses persisted in 60% to 83% of participants receiving Ad26.ZEBOV first followed by MVA-BN-Filo as a booster compared with 69% to 100% of those receiving the reverse regimen (Table) . Persistence of the CD8+ and CD4+ responses is shown in the Table. Discussion | Immunity after heterologous primary and booster vaccination with Ad26.ZEBOV and MVA-BN-Filo persisted at 1 year. Although no correlate of protection has yet been established, Ebola virus glycoprotein-specific antibodies appear to play an important role in immunity.
5 A strategy of preemptive use of an AD26.ZEBOV followed by MVA-BN-Filo immunization schedule in at-risk populations (where durability of immune response is likely to be of primary importance) may offer advantages over reactive use of a Responders for ELISA, ELISpot, or intracellular cytokine staining were those participants whose results were negative at baseline and positive after baseline or positive at baseline with at least 3-fold increase from baseline. b ELISpot on frozen peripheral blood mononuclear cells shown as number of SFUs per million cells.
